Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study

Masatoshi Kudo, Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Hiroshi Aikata, Atsushi Hiraoka, Michihisa Moriguchi, Ryosuke Tateishi, Sadahisa Ogasawara, Kouji Yamamoto, Masafumi Ikeda

Open source

DOI: 10.1159/000546899
Published: 2025-06-19
Container: Liver Cancer
Publisher: S. Karger AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1159/000546899,
  title = {Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study},
  author = {Masatoshi Kudo and Kazuomi Ueshima and Kaoru Tsuchiya and Tatsuya Yamashita and Shigeo Shimose and Kazushi Numata and Yuzo Kodama and Shinji Itoh and Yasuhito Tanaka and Hidekatsu Kuroda and Hiroshi Aikata and Atsushi Hiraoka and Michihisa Moriguchi and Ryosuke Tateishi and Sadahisa Ogasawara and Kouji Yamamoto and Masafumi Ikeda},
  year = {2025},
  journal = {Liver Cancer},
  doi = {10.1159/000546899},
  url = {https://doi.org/10.1159/000546899}
}

RIS

TY  - JOUR
TI  - Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study
AU  - Masatoshi Kudo
AU  - Kazuomi Ueshima
AU  - Kaoru Tsuchiya
AU  - Tatsuya Yamashita
AU  - Shigeo Shimose
AU  - Kazushi Numata
AU  - Yuzo Kodama
AU  - Shinji Itoh
AU  - Yasuhito Tanaka
AU  - Hidekatsu Kuroda
AU  - Hiroshi Aikata
AU  - Atsushi Hiraoka
AU  - Michihisa Moriguchi
AU  - Ryosuke Tateishi
AU  - Sadahisa Ogasawara
AU  - Kouji Yamamoto
AU  - Masafumi Ikeda
PY  - 2025
JO  - Liver Cancer
DO  - 10.1159/000546899
UR  - https://doi.org/10.1159/000546899
ER  -

APA

Kudo, M., Ueshima, K., Tsuchiya, K., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Itoh, S., Tanaka, Y., Kuroda, H., Aikata, H., Hiraoka, A., Moriguchi, M., Tateishi, R., Ogasawara, S., Yamamoto, K., & Ikeda, M. (2025). Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACEMENT Study. Liver Cancer. https://doi.org/10.1159/000546899

Source records

crossref · retrieved 2026-09-25T00:31:00.804Z